Steven M. Koenig
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Steven M. Koenig has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Paul Dorinsky
2 shared publicationsBarbara A. Prillaman
1 shared publicationBarbara Prillaman
1 shared publicationDavid Pearlman
1 shared publicationJames Wolfe
1 shared publicationJohn J. Murray
1 shared publication
Latest Publications
- 1 May 2008
- Published by Elsevier in Respiratory Medicine
- Vol. 102 (5) , 665-673
Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
- 1 May 2008
- Published by Elsevier in Respiratory Medicine
- Vol. 102 (5) , 665-673
Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent asthma?
- 1 January 2008
- Published by Taylor & Francis in Journal of Asthma
- Vol. 45 (8) , 681-687
Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are “Stepped-Down”
In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100 mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, "stepping down" to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS.
- 1 January 2008
- Published by Taylor & Francis in Journal of Asthma
- Vol. 45 (8) , 681-687
Deterioration in Asthma Control When Subjects Receiving Fluticasone Propionate/Salmeterol 100/50 mcg Diskus are “Stepped-Down”
In this study, 647 subjects stable on fluticasone propionate/salmeterol Diskus 100/50 mcg BID (FSC) were randomized to continue FSC 100/50 mcg BID or "step down" to either fluticasone propionate (FP) 100 mcg BID, salmeterol (SAL) 50 mcg BID, or montelukast (MON) 10 mg once daily for 16 weeks. Overall asthma control significantly improved in the FSC group; whereas, "stepping down" to FP, SAL, or MON resulted in deterioration in asthma control, as determined by decreased measures of lung function and clinical features. This study provides support that treatment of both inflammation and smooth muscle dysfunction may be necessary to achieve and maintain asthma control in patients uncontrolled on ICS.
- 1 April 2001
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 321 (4) , 249-279
Pulmonary Complications of Obesity
- 1 April 2001
- Published by Elsevier in The American Journal of the Medical Sciences
- Vol. 321 (4) , 249-279
Pulmonary Complications of Obesity